CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection

  title={CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection},
  author={Mike Westby and E van der Ryst},
  journal={Antiviral Chemistry and Chemotherapy},
  pages={339 - 354}
The human chemokine receptors, CCR5 and CXCR4, are potential host targets for exogenous, small-molecule antagonists for the inhibition of HIV-1 infection. HIV-1 strains can be categorised by co-receptor tropism — their ability to utilise CCR5 (CCR5-tropic), CXCR4 (CXCR4-tropic) or both (dual-tropic) as a co-receptor for entry into susceptible cells. CCR5 may be the more suitable co-receptor target for small-molecule antagonists because a natural deletion in the CCR5 gene preventing its… 

Figures and Tables from this paper

Maraviroc: the first chemokine coreceptor 5 inhibitor

Since marviroc is only efficacious against CCR5-tropic HIV virus, it is imperative to perform viral tropism testing prior to initiation of maraviroc, and the currently available enhanced sensitivity Trofile™ assay is the reference standard of tropism tests.

Progress in HIV-1 Prevention, Control and Treatment: Genetic Manipulation or Pharmacological Blockade of Chemokine Receptor 5?

The current trend in HIV-1 control, prevention and treatment is highlighted, and the two promising approaches are compared: Genetic manipulation of CCR5 gene and the pharmacological blockade of C CR5 using chemokine receptor antagonists.

CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on

The field is revisited and the clinical and virological data that have emerged in the 4 years since are assessed, with particular reference to maraviroc for which the most comprehensive data currently exist.

Biology of CCR5 and its role in HIV infection and treatment.

The effects that targeting CCR5 may have on host defenses in individuals with immunity already compromised by HIV infection are explored.

Maraviroc in Antiretroviral-Naïve HIV-1 Patients

Evidences from trials suggest that maraviroc is effective at reducing HIV-1 viral load in antiretroviral-experienced and -naïve patients with CCR5-tropic virus, as well as in those who have developed HIV- 1 resistance to existing antireTroviral regimens.

Oral CCR5 inhibitors: will they make it through?

The therapeutic armamentarium against HIV has recently gained a drug belonging to a novel class of antiretrovirals, the entry inhibitors, and promising small-molecule, orally bioavailable CCR5 antagonists are under development for the treatment of HIV-1 infection.



Assessing chemokine co-receptor usage in HIV

The development of rapid, reliable tropism assays has been useful in advancing the development of novel antiviral agents and defining the role of these assays in routine clinical practice will be the next important step.

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

  • M. BabaO. Nishimura M. Fujino
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TAK-779 displayed highly potent and selective inhibition of R5 HIV-1 replication without showing any cytotoxicity to the host cells, and the inhibition of beta-chemokine receptors appeared to be specific to CCR5.

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

The mechanism of action of two inhibitors of CCR5 function are identified, SCH-350581 (AD101) and SCH-351125 (SCH-C), which are more potent than SCH-C at inhibiting HIV-1 replication in primary lymphocytes, as well as viral entry and gp120 binding to cell lines.

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

In addition to CD4, the human immunodeficiency virus (HIV) requires a coreceptor for entry into target cells. The chemokine receptors CXCR4 and CCR5, members of the G protein-coupled receptor

CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro

Anti-CCR5 mAbs were poor inhibitors of chemokine binding, indicating that HIV-1 and ligands bind to separate, but overlapping regions of CCR5, and demonstrate the feasibility of blocking macrophage-tropic HIV- 1 entry into cells with an anti-CCr5 reagent.

The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates

Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

CCR5-targeting agents such as PRO 140 can demonstrate potent and genetic-subtype-independent anti-HIV-1 activity.

Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist

AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction and blocks R5 and X4 HIV-1 infection at the virus entry stage.

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

  • P. LinW. Blair R. Colonno
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors, and displays many favorable pharmacological traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicology studies.